CN1488641A - Polypeptide medicine for inhibiting SARS coronavirus, and derivatives and use thereof - Google Patents
Polypeptide medicine for inhibiting SARS coronavirus, and derivatives and use thereof Download PDFInfo
- Publication number
- CN1488641A CN1488641A CNA031362206A CN03136220A CN1488641A CN 1488641 A CN1488641 A CN 1488641A CN A031362206 A CNA031362206 A CN A031362206A CN 03136220 A CN03136220 A CN 03136220A CN 1488641 A CN1488641 A CN 1488641A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- derivative
- sars coronavirus
- sars
- albumen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 69
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 67
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 63
- 241000315672 SARS coronavirus Species 0.000 title claims abstract description 40
- 239000003814 drug Substances 0.000 title claims description 9
- 230000002401 inhibitory effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 22
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 claims abstract description 11
- 230000000903 blocking effect Effects 0.000 claims abstract 2
- 150000001413 amino acids Chemical group 0.000 claims description 18
- 238000005267 amalgamation Methods 0.000 claims description 6
- 235000001014 amino acid Nutrition 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 238000003780 insertion Methods 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 3
- 102000005720 Glutathione transferase Human genes 0.000 claims 2
- 108010070675 Glutathione transferase Proteins 0.000 claims 2
- 230000008034 disappearance Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 17
- 102000004169 proteins and genes Human genes 0.000 abstract description 10
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 241001597008 Nomeidae Species 0.000 abstract 1
- 238000004581 coalescence Methods 0.000 abstract 1
- 101100071394 Arabidopsis thaliana HR2 gene Proteins 0.000 description 49
- 101100071393 Arabidopsis thaliana HR1 gene Proteins 0.000 description 45
- 101100220069 Homo sapiens CDCA7L gene Proteins 0.000 description 45
- 210000004027 cell Anatomy 0.000 description 18
- 241000711573 Coronaviridae Species 0.000 description 12
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 10
- 230000004927 fusion Effects 0.000 description 10
- 239000007788 liquid Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 7
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 6
- 238000013016 damping Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000009210 therapy by ultrasound Methods 0.000 description 6
- 101150093250 HR1 gene Proteins 0.000 description 5
- 101150036375 HR2 gene Proteins 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 230000029087 digestion Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 3
- CFBILACNYSPRPM-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]acetic acid Chemical compound OCC(N)(CO)CO.OCC(CO)(CO)NCC(O)=O CFBILACNYSPRPM-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 235000003969 glutathione Nutrition 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 102100031673 Corneodesmosin Human genes 0.000 description 2
- 101710139375 Corneodesmosin Proteins 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- UMYZBHKAVTXWIW-GMOBBJLQSA-N Ile-Asp-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N UMYZBHKAVTXWIW-GMOBBJLQSA-N 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- DFQZDQPLWBSFEJ-LSJOCFKGSA-N Val-Val-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)N DFQZDQPLWBSFEJ-LSJOCFKGSA-N 0.000 description 2
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000012407 engineering method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000012716 precipitator Substances 0.000 description 2
- 238000002331 protein detection Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000002277 temperature effect Effects 0.000 description 2
- 108010046845 tryptones Proteins 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 1
- XWGJDUSDTRPQRK-ZLUOBGJFSA-N Asn-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(N)=O XWGJDUSDTRPQRK-ZLUOBGJFSA-N 0.000 description 1
- QNJIRRVTOXNGMH-GUBZILKMSA-N Asn-Gln-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(N)=O QNJIRRVTOXNGMH-GUBZILKMSA-N 0.000 description 1
- QPTAGIPWARILES-AVGNSLFASA-N Asn-Gln-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QPTAGIPWARILES-AVGNSLFASA-N 0.000 description 1
- ZMUQQMGITUJQTI-CIUDSAMLSA-N Asn-Leu-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O ZMUQQMGITUJQTI-CIUDSAMLSA-N 0.000 description 1
- RCFGLXMZDYNRSC-CIUDSAMLSA-N Asn-Lys-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O RCFGLXMZDYNRSC-CIUDSAMLSA-N 0.000 description 1
- JBDLMLZNDRLDIX-HJGDQZAQSA-N Asn-Thr-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O JBDLMLZNDRLDIX-HJGDQZAQSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010003757 Atypical pneumonia Diseases 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- KVYVOGYEMPEXBT-GUBZILKMSA-N Gln-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O KVYVOGYEMPEXBT-GUBZILKMSA-N 0.000 description 1
- INFBPLSHYFALDE-ACZMJKKPSA-N Gln-Asn-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O INFBPLSHYFALDE-ACZMJKKPSA-N 0.000 description 1
- ZNZPKVQURDQFFS-FXQIFTODSA-N Gln-Glu-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZNZPKVQURDQFFS-FXQIFTODSA-N 0.000 description 1
- HDUDGCZEOZEFOA-KBIXCLLPSA-N Gln-Ile-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CCC(=O)N)N HDUDGCZEOZEFOA-KBIXCLLPSA-N 0.000 description 1
- LPIKVBWNNVFHCQ-GUBZILKMSA-N Gln-Ser-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LPIKVBWNNVFHCQ-GUBZILKMSA-N 0.000 description 1
- XKPACHRGOWQHFH-IRIUXVKKSA-N Gln-Thr-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XKPACHRGOWQHFH-IRIUXVKKSA-N 0.000 description 1
- IDEODOAVGCMUQV-GUBZILKMSA-N Glu-Ser-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IDEODOAVGCMUQV-GUBZILKMSA-N 0.000 description 1
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 1
- OVSKVOOUFAKODB-UWVGGRQHSA-N Gly-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N OVSKVOOUFAKODB-UWVGGRQHSA-N 0.000 description 1
- XBWMTPAIUQIWKA-BYULHYEWSA-N Gly-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CN XBWMTPAIUQIWKA-BYULHYEWSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- LKACSKJPTFSBHR-MNXVOIDGSA-N Ile-Gln-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N LKACSKJPTFSBHR-MNXVOIDGSA-N 0.000 description 1
- GVKKVHNRTUFCCE-BJDJZHNGSA-N Ile-Leu-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)O)N GVKKVHNRTUFCCE-BJDJZHNGSA-N 0.000 description 1
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 1
- KKXDHFKZWKLYGB-GUBZILKMSA-N Leu-Asn-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N KKXDHFKZWKLYGB-GUBZILKMSA-N 0.000 description 1
- MYGQXVYRZMKRDB-SRVKXCTJSA-N Leu-Asp-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN MYGQXVYRZMKRDB-SRVKXCTJSA-N 0.000 description 1
- ZYLJULGXQDNXDK-GUBZILKMSA-N Leu-Gln-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ZYLJULGXQDNXDK-GUBZILKMSA-N 0.000 description 1
- LIINDKYIGYTDLG-PPCPHDFISA-N Leu-Ile-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LIINDKYIGYTDLG-PPCPHDFISA-N 0.000 description 1
- GZRABTMNWJXFMH-UVOCVTCTSA-N Leu-Thr-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZRABTMNWJXFMH-UVOCVTCTSA-N 0.000 description 1
- VJGQRELPQWNURN-JYJNAYRXSA-N Leu-Tyr-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O VJGQRELPQWNURN-JYJNAYRXSA-N 0.000 description 1
- RZHLIPMZXOEJTL-AVGNSLFASA-N Lys-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)N RZHLIPMZXOEJTL-AVGNSLFASA-N 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241001643857 Menangle virus Species 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- JJHVFCUWLSKADD-ONGXEEELSA-N Phe-Gly-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](C)C(O)=O JJHVFCUWLSKADD-ONGXEEELSA-N 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- YPUSXTWURJANKF-KBIXCLLPSA-N Ser-Gln-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O YPUSXTWURJANKF-KBIXCLLPSA-N 0.000 description 1
- IOVHBRCQOGWAQH-ZKWXMUAHSA-N Ser-Gly-Ile Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O IOVHBRCQOGWAQH-ZKWXMUAHSA-N 0.000 description 1
- WLJPJRGQRNCIQS-ZLUOBGJFSA-N Ser-Ser-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O WLJPJRGQRNCIQS-ZLUOBGJFSA-N 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- RVMNUBQWPVOUKH-HEIBUPTGSA-N Thr-Ser-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RVMNUBQWPVOUKH-HEIBUPTGSA-N 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- RUCNAYOMFXRIKJ-DCAQKATOSA-N Val-Ala-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN RUCNAYOMFXRIKJ-DCAQKATOSA-N 0.000 description 1
- XGJLNBNZNMVJRS-NRPADANISA-N Val-Glu-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O XGJLNBNZNMVJRS-NRPADANISA-N 0.000 description 1
- FEXILLGKGGTLRI-NHCYSSNCSA-N Val-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N FEXILLGKGGTLRI-NHCYSSNCSA-N 0.000 description 1
- UQMPYVLTQCGRSK-IFFSRLJSSA-N Val-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N)O UQMPYVLTQCGRSK-IFFSRLJSSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 108010090037 glycyl-alanyl-isoleucine Proteins 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides a method for blocking SARS coronavirus to infect cell with polypeptide or its derivative. The cistine series of polypeptide comes from two heptad repeat districts HR1 and HR2 of SARS coronavirus spike(S) protein. The invention also provides a method for producing the functional similarity with HR1 and HR2. the invention provides a method for producing HR polypeptide and its derivant with coalescence expression method. All the peptides have rejection capability to SARS.
Description
Invention field:
The invention belongs to the biology field of virus.Concretely, relate to and utilize proteic seven peptides of sars coronavirus spike (S) to repeat that (heptad repeat, HR) HR1 and HR2 polypeptide and derivative thereof carry out control that sars coronavirus is infected.
Background technology:
In worldwide, broken out a kind of communicable severe acute respiratory syndrome (Severe Acute Respiratory Syndrome recently, SARS) or claim " atypical pneumonia ", its cause of disease tentatively is defined as a kind of novel coronavirus (Coronavirus) at present.Coronavirus is a kind of RNA viruses with cyst membrane, and is similar with other togavirus, and it need be discharged into genetic material the infection of finishing pair cell in the cell by the fusion of virus envelope and cytolemma.Syncretizing mechanism to most of togavirus is discovered, they all are to utilize the fusion of cyst membrane fusion glycoprotein by conformational change mediation virus envelope and host cell membrane, these membrane glycoproteins are (as the HA of influenza virus, the gp120/gp41 of HIV, the F albumen of Gp of Ebola virus and respiratory syncytial virus) similar constitutional features is arranged, they all have two sections to be called seven peptides repetition (heptad repeat, HR) zone-HR1 and HR2, these two sections zones can form a kind of six stable helical bundles or claim hair fastener tripolymer structure when albumen performance fusion-activity, this structure is most important by conformational change performance fusion function to albumen, many external sources that studies show that add formation hair fastener tripolymer between HR1 that HR1 or HR2 polypeptide can blocks protein itself and HR2, thereby suppressed the fusion of virus envelope and cytolemma, finally stoped the infection of viral pair cell.Yet, yet there are no report so far according to this characteristics design polypeptide or its analogue medicine as the control coronavirus infection.Only having medicine-T-20 (HR2 polypeptide derivative) that report enters phase iii clinical trial at present in the treatment of acquired immune deficiency syndrome (AIDS), is exactly the representative of this class medicine, and its therapeutic action effect is fine.
Summary of the invention:
Be called seven peptides repeat (Heptad Repeat, in research HR), this research group has made related work in multiple virus, as human respiratory syncytial precursor virus (Wang, E., Sun, X., Qian, Y., Zhao, L., Tien, P.and Gao, G.F., BBRC.2003,302:469-475.), Measles virus (Zhu, J., Zhang, C.W-H., Qi, Y., Tien, P.and Gao, G.F., BBRC. 2002,299:897-902.; Zhu, J., Ding, Y., Gao, F., Wu, T., Zhang, C.W-H., Tien, P., Rao, Z.and Gao, G.F.ActaCrystallogr Biol Crystallogr.2003, D59:587-590.), emerging Menangle virus (Zhu, J., Zhang, C.W-H., Rao, Z.Tien, P.and Gao, G.F.Archives of Virology2003, in press) etc., newcastle disease virus (Yu, M., Wang, E., Liu, Y., Cao, D., Jin, N., Zhang, C.W-H., Bartlam, M., Rao, Z., Tien, P.and Gao, G.F.Journal of General Virology 2002,83 (Pt3): 623-629; Zhu, J., Li, P., Wu, T., Zhang, C.W-H., Bartlam, M., Rao, Z., Gao, G.F and Tien, P.Protein Engineering 2003, inpress) etc.The six helical bundle structures and the virus that have confirmed them merge the inhibition test of invasion.We set up by technology platform in this respect.
The membrane glycoprotein that participates in the coronavirus fusion is spike (S) albumen, after the complete sequence of sars coronavirus is finished (Canada), the present invention has carried out systems analysis to its encoded protein matter, find also to have on the Spike albumen two sections distinctive seven peptides to repeat (Heptad Repeat, HR1 and HR2), its position in S albumen is please referring to Fig. 1, also compared the position of this zone of hiv virus in envelope protein (GP160) among the figure, this hint sars coronavirus may have similar syncretizing mechanism to HIV etc.We have also further compared all sars coronavirus sequences in gene pool (GenBank), comprise from the U.S., Canada, Hong Kong, Beijing, the virus genome sequence in Guangdong etc. finds that HR1 and this zone of HR2 are high conservatives, therefore, the resistance that can avoid the sars coronavirus variation to cause as drug target with them.For this reason, the object of the present invention is to provide the method for a kind of HR1 of utilization and HR2 polypeptide and derivative thereof blocking-up sars coronavirus cells infected, wherein amino acid sequence of polypeptide is from proteic two heptad repeat region (the heptad repeat of sars coronavirus spike (S), HR) HR1 and HR2, the invention provides sars coronavirus spike albumen HR1 and HR2 district position and the aminoacid sequence on albumen, wherein HR1 has the aminoacid sequence shown in Seq ID:No.1; HR2 has the aminoacid sequence shown in Seq ID:No.2; Should be pointed out that above-mentioned sequence is carried out one or more amino acid whose replacements, insertion and/or lack resulting functional analogue also reaching purpose of the present invention.Another object of the present invention also is to provide the method for a kind of HR1 of design and HR2 polypeptide functional analogue; The present invention also provides a kind of method of utilizing amalgamation and expression to prepare sars coronavirus S albumen HR polypeptide or derivatives thereof.This HR polypeptide and the derivative thereof that obtains by expression and purification or artificial synthesis all has the activity of inhibition to the SARS virus cells infected, can be developed into the polypeptide drugs of control SARS disease.
The invention provides following two kinds of methods and obtain HR polypeptide or derivatives thereof:
1. artificial synthetic polypeptide
According to proteic HR1 of sars coronavirus spike provided by the invention and HR2 sequence, synthetic corresponding to the polypeptide of HR1 and HR2, identify that through HPLC purity is greater than 90%.
2. gene engineering method
(1) prepares HR1 and HR2 polypeptide or derivatives thereof with the GST amalgamation and expression
Aminoacid sequence and intestinal bacteria preference codon according to SARS virus S albumen HR1 and HR2, HR1 and HR2 gene are manually spliced, utilize BamH I/Xho I restriction enzyme site to be cloned among the GST fusion expression vector pGEX-6p-1, determine that through determined dna sequence the gained gene order is correct.With pGEX-6p-1/HR1 and pGEX-6p-1/HR2 difference transformed into escherichia coli BL21 (DE3) competent cell, select an amount of 2 * YTA liquid nutrient medium (Tryptones 16g that the mono-clonal inoculation contains acillin (100 μ g/ml), yeast extract 10g, sodium-chlor 5g, water 1000ml), 37 ℃ of shake overnight incubation are as seed liquor; Seed liquor is inoculated fresh 2 * YTA liquid nutrient medium by 1/100 inoculum size, and 37 ℃ of shakes are cultured to OD
590For about 0.8-1.0, add inductor IPTG to final concentration 1mM, 37 ℃ or 28 ℃ are continued to cultivate 4h; The centrifugal 15min of 5000rpm collects thalline, adds an amount of PBS damping fluid (140mM NaCl, 2.7mM KCl, 10mM Na
2HPO
4, 1.8mM KH
2PO
4, pH7.3) resuspended thalline, the ultrasonic treatment thalline, the adding final concentration is 1% TritonX-100 behind the ultrasonic treatment, ice bath 30min, 12000rpm, 4 ℃ of centrifugal 15min get supernatant; The ultrasonic treatment supernatant by through PBS equilibrated Glutathione-Sepharose 4B affinity column, is washed at least ten column volumes of affinity column with PBS again; Reduced glutathion solution (10mM reduced glutathione with at least three column volumes, 50mM Tris-HCl pH8.0) wash-out, collect elutriant and obtain GST-HR albumen, method with Superdex G50 desalting column (Pharmacia company) or ultrafiltration and concentration redilution changes enzyme cutting buffering liquid (50mMTris-HCl, pH7.0 into; 150mM NaCl; 1mM DTT; 1mM EDTA pH8.0), adds 5 ℃ of enzymes of excessive GST-3C proteolytic enzyme and cuts 16h; Enzyme is cut product and is changed the PBS damping fluid again into, with affine GST and the GST-3C that removes the enzyme cutting-out of Glutathione-Sepharose 4B affinity column, collection penetrates liquid and obtains HR1 or HR2 albumen, with the molecular weight that dams is that the ultrafiltration pipe of 3K is concentrated into proper concn, utilize reverse hplc to be further purified ,-70 ℃ frozen standby.Protein sample is identified with 12%SDS-PAGE or Tris-tricine SDS-PAGE.Protein concentration is determined with BCA protein detection kit (Pierce company).
(2) prepare HR1 and HR2 polypeptide or derivatives thereof with people GST protein fusion expression
With people GST protein gene and sars coronavirus spike albumen HR1 and the fusion of HR2 or derivatives thereof, fusion rotein is directly used in the infection that suppresses the sars coronavirus pair cell.
The invention provides the method for design sars coronavirus spike albumen HR1 and HR2 polypeptide functional analogue.Because the hydrophobicity of HR1 polypeptide is stronger, very easy generation self is assembled, and stability is bad, and this has just influenced the performance of its function.The present invention with the amino acid connexon with HR1, HR2, HR1 be together in series (being called HR121) express and purifying, simultaneously HR1, HR2, HR1, HR2, five polypeptide of HR1 are together in series (being called 5-Helix) express and purifying, gained HR121 and 5-Helix stability are higher than independent HR1 polypeptide, and function is identical with it.The present invention also HR2, HR1, three polypeptide of HR2 are together in series (being called HR212) express and purifying, gained HR212 albumen is more stable and be convenient to purifying than independent HR2 polypeptide equally, and function is similar to it.
The invention provides the method for using sars coronavirus spike albumen HR1 and HR2 polypeptide or derivatives thereof blocking-up SARS virus cells infected.Mix with the sars coronavirus of fixed concentration with the HR polypeptide of above synthetic or gene engineering method acquisition or with the HR albumen doubling dilution of GST or the fusion of other albumen, culturing cell such as co-absorbed Vero then, observe HR polypeptide or GST-HR produce cytopathy (CPE) to sars coronavirus influence, the result shows that HR polypeptide or GST-HR can suppress the generation of CPE in the nM concentration range, illustrate that the HR polypeptide can block the infection of sars coronavirus pair cell, HR polypeptide or derivatives thereof provided by the present invention can be used to develop prevents and treats the medicine that SARS virus infects.
Brief Description Of Drawings:
Fig. 1 sars coronavirus spike (S) protein structure synoptic diagram.Illustrate two subunits of possible S1 and S2 and stride film district (transmembrane domain) and cytoplasmic region (cytoplamicdomain).The HR1 of computer program prediction and HR2 be in the proteic corresponding position of S, and predicting the outcome with the HR1 of HIV-1gp160 and HR2 simultaneously compares, and illustrates that they have similar constitutional features.
Fig. 2 makes up HR1 and HR2 polypeptide functional analogue synoptic diagram.5-Helix is HRllinker1HR2linker2HR1linker1HR2linker2HR1, HR121 is HR1linker1HR2linker2HR1, HR212 is HR2linker2HR1linker1HR2, wherein the aminoacid sequence of linker1 is SGGRGG (the amino acid whose english abbreviation of letter representation), and the aminoacid sequence of linker2 is GGSGG (the amino acid whose english abbreviation of letter representation).The function class of 5-Helix and HR121 and HR1 polypeptide seemingly, the function class of HR212 and HR2 polypeptide is seemingly.
Embodiment:
Embodiment
1.SARS from the Toronto strain isolated, include number and be: NC_004718 by gene pool with sars coronavirus S protein sequence for the forecasting institute in coronavirus spike (S) albumen HR1 and HR2 district.Utilize computer program that S albumen is analyzed, show that sars coronavirus S albumen has two typical seven peptide tumor-necrosis factor glycoproteinss, utilize other different program to analyze simultaneously, the position of HR1 and HR2 is similar as a result, determines that at last the HR1 sequence is Seq ID:No.1; The HR2 sequence is Seq ID:No.2.
2.SARS the synthetic of coronavirus S albumen HR1 and HR2 polypeptide
According to HR1 and the HR2 aminoacid sequence that embodiment 1 is provided, synthetic the HR2 polypeptide, synthesized the HR1 polypeptide of three sections different lengthss simultaneously, identify that through HPLC purity is more than 90%, and institute's synthetic peptide solubility is fine.
3.SARS the artificial splicing of coronavirus S albumen HR1 gene
HR1 sequence that is provided according to embodiment 1 and intestinal bacteria preference codon have designed following ten primers and have been used to splice the HR1 gene:
S(hr1)1：5’gat?gga?tcc?gag?aac?cag?aaa?cag?atc?gcc?aac?cag?ttc?aac?aag?gcg?atc?3’
S(hr1)2：5’?tga?ggt?cgt?ggt?aag?tga?ttc?ttg?aat?ttg?act?gat?cgc?ctt?gtt?gaa?ctg?3’
S(hr1)3：5’?tca?ctt?acc?acg?acc?tca?act?gca?ttg?ggc?aag?ctg?cag?gac?gtt?gtt?aac?3’
S(hr1)4：5’?ttt?cac?cag?cgt?gtt?cag?tgc?ttg?agc?att?ctg?gtt?aac?aac?gtc?ctg?cag?3’
S(hr1)5：5’?ctg?aac?acg?ctg?gtg?aaa?caa?ctt?agc?tct?aat?ttt?ggt?gcg?att?tca?agt?gtg?3
S(hr1)6：5’?gac?ttt?atc?cag?acg?cga?aag?gat?atc?att?cag?cac?act?tga?aat?cgc?acc?3’
S(hr1)7：5’?tcg?cgt?ctg?gat?aaa?gtc?gag?gcg?gag?gta?caa?atc?gac?cgt?ctg?atc?acc?3’
S(hr1)8：5’?tgt?cac?ata?ggt?ctg?cag?gct?ttg?aag?acg?gcc?ggt?gat?cag?acg?gtc?gat?3’
S(hr1)9：5’?ctg?cag?acc?tat?gtg?aca?caa?caa?ctg?atc?cgt?gct?gct?gaa?atc?cgt?gct?3’
S(hr1)10：5’gac?ctc?gag?tca?agc?aag?att?agc?aga?agc?acg?gat?ttc?agc?agc?3’
Wherein per two adjacent primers all have the complementary sequence of 18 bases, and design simultaneously has BamH I and Xho I restriction enzyme site and termination codon.The primer synthetic.Splice the HR1 gene by following method: the first step, mix 100 primers of S (hr1) 1-S (hr1) (0.2OD/ μ l), increase by following PCR condition: 94 ℃ of sex change 5min, then carry out 94 ℃ of 1.5min, 55 ℃ of 2min, 72 ℃ of 1min, 25 circulations; Second step was a primer with S (hrl) 1 and S (hr1) 10, and the first step PCR product is a template, carries out pcr amplification by same condition.The dehydrated alcohol precipitator method reclaim the PCR product, and 1% agarose electrophoresis is identified.The gained gene with BamH I and Xho I double digestion, and is connected through the pGEX-6p-1 of double digestion carrier equally, cuts the method screening positive clone of evaluation by enzyme, after determined dna sequence proves that gained HR1 gene is entirely true.
4.SARS the splicing of coronavirus S albumen HR2 gene
HR2 sequence that is provided according to embodiment 1 and intestinal bacteria preference codon have designed following four primers and have been used to splice the HR2 gene:
S(hr2)1：5’gac?gga?tcc?ggc?gac?att?tca?ggc?att?aac?gct?tct?gtc?gtc?aac?att?3’
S(hr2)2：5’gac?ctc?att?gag?acg?atc?aat?ttc?ttt?ttg?aat?gtt?gac?gac?aga?agc?3’
S(hr2)3：5’gat?cgt?ctc?aat?gag?gtc?gct?aaa?aat?tta?aac?gaa?tca?ctg?atc?gac?3’
S(hr2)4：5’gta?ctc?gag?tca?gcc?caa?ttc?ttg?cag?gtc?gat?cag?tga?ttc?g?3’
Wherein per two adjacent primers all have the complementary sequence of 18 bases, and design simultaneously has BamH I and Xho I restriction enzyme site and termination codon.The primer synthetic.Splice the HR2 gene by following method: the first step, mix 4 four primers of S (hr2) 1-S (hr2) (0.2OD/ μ l), increase by following PCR condition: 94 ℃ of sex change 5min, then carry out 94 ℃ of 1min, 55 ℃ of 2min, 72 ℃ of 1min, 25 circulations; Second step was a primer with S (hr2) 1 and S (hr2) 4, and the first step PCR product is a template, carries out pcr amplification by same condition.The dehydrated alcohol precipitator method reclaim the PCR product, and 1% agarose electrophoresis is identified.The gained gene with BamH I and Xho I double digestion, and is connected through the pGEX-6p-1 of double digestion carrier equally, cuts the method screening positive clone of evaluation by enzyme, after determined dna sequence proves that gained HR2 gene is entirely true.
5.SARS the amalgamation and expression of coronavirus HR1 and HR2 polypeptide
Will be through dna sequencing pGEX-6p-1/HR1 and pGEX-6p-1/HR2 difference transformed into escherichia coli BL21 (DE3) competent cell, select an amount of 2 * YTA liquid nutrient medium (Tryptones 16g that the mono-clonal inoculation contains acillin (100 μ g/ml), yeast extract 10g, sodium-chlor 5g, water 1000ml), 37 ℃ of shake overnight incubation are as seed liquor; Seed liquor is inoculated fresh 2 * YTA liquid nutrient medium by 1/100 inoculum size, and 37 ℃ of shakes are cultured to OD
590For about 0.8-1.0, add inductor IPTG to final concentration 1mM, 37 ℃ or 28 ℃ are continued to cultivate 4h; The centrifugal 15min of 5000rpm collects thalline, adds an amount of PBS damping fluid (140mM NaCl, 2.7mM KCl, 10mM Na
2HPO
4, 1.8mM KH
2PO
4, pH7.3) resuspended thalline, the ultrasonic treatment thalline, the adding final concentration is 1% TritonX-100 behind the ultrasonic treatment, ice bath 30min, 12000rpm, 4 ℃ of centrifugal 15min get supernatant; The ultrasonic treatment supernatant by through PBS equilibrated Glutathione-Sepharose 4B affinity column, is washed at least ten column volumes of affinity column with PBS again; Reduced glutathion solution (10mM reduced glutathione with at least three column volumes, 50mM Tris-HCl pH8.0) wash-out, collect elutriant and obtain GST-HR albumen, identify that through 12%SDS-PAGE the gained molecular weight of albumen conforms to expection, wherein GST-HR1 is about 38kDa, and GST-HR2 is about 30kDa; Method with Superdex G50 desalting column (Pharmacia company) or ultrafiltration and concentration redilution changes GST-HR into enzyme cutting buffering liquid (50mM Tris-HCl, pH7.0; 150mM NaCl; 1mMDTT; 1mM EDTA pH8.0), adds 5 ℃ of enzymes of excessive GST-3C proteolytic enzyme and cuts 16h; Enzyme is cut product and is changed the PBS damping fluid again into, with affine GST and the GST-3C that removes the enzyme cutting-out of Glutathione-Sepharose 4B affinity column, collection penetrates liquid and obtains HR1 or HR2 albumen, with the molecular weight that dams is that the ultrafiltration pipe of 3K is concentrated into proper concn, utilize reverse hplc to be further purified ,-70 ℃ frozen standby.Protein sample identifies that with 12%Tris-tricine SDS-PAGE gained HR1 polypeptide is about 12kDa as a result, and the HR2 polypeptide is about 4kDa, conforms to the expection size.Protein concentration is determined with BCA protein detection kit (Pierce company).
6.SARS the amalgamation and expression of coronavirus HR1 and HR2 polypeptide and people GST
By similarly to Example 5 method amalgamation and expression and purifying, the GST-HR albumen that obtains is directly used in and detects it to suppressing activity of sars coronavirus cells infected with people GST and HR1 or HR2 polypeptide.
7.SARS the external combination of coronavirus S albumen HR1 and HR2 polypeptide
To mix with the HR2 of expression and purification or the HR2 polypeptide of synthetic by the GST-HR1 of embodiment 5 method purifying, room temperature effect 1 hour, mix with the affine filler of an amount of Glutathione-Sepharose 4B again, the room temperature effect was washed three times with the PBS damping fluid after 30 minutes, then use the reduced glutathion eluant solution, carrying out 12%Tris-tricine SDS-PAGE at last identifies, the result shows that GST-HR1 can combine with the HR2 polypeptid specificity of expression and purification or synthetic, illustrates that HR1 or HR2 polypeptide and derivative thereof are to suppress active by combining with corresponding HR district on the virus S protein to bring into play.
8. the HR polypeptide or derivatives thereof that obtains of embodiment 2,5 and 6 methods infects the inhibition of culturing cell to SARS virus
Vero E6 cell cultures in DMEM substratum (containing the 100U/ml mycillin, 10% foetal calf serum), 37 ℃, 5%CO
2Be cultured in the incubator and grow into individual layer.With HR polypeptide and derivative (being dissolved in the PBS damping fluid) filtration sterilization thereof that embodiment 2,5 and 6 methods obtain, the sars coronavirus of doubling dilution (initial concentration is 100 μ M) back and fixed concentration mixes (viral TCID
50Be 5) amount to the above-mentioned cell of absorption, 37 ℃ after 1 hour, inhale the mixture of abandoning virus and peptide, adding DMEM keeps liquid (containing the 100U/ml mycillin, 2% foetal calf serum), 37 ℃, 5%CO
2Continue in the incubator to cultivate, each extent of dilution was done 8 repetitions, every 12 hours observation of cell pathology (CPE) situations.The CPE that sars coronavirus produces on the Vero cell is that cell rounding, atrophy, refractivity are strong, last cell detachment.Calculate the quantity in each repressed hole of extent of dilution CPE, carry out statistical study, calculate IC at last
50Value.The result shows that HR2 polypeptide or GST-HR2 can both suppress sars coronavirus and produce CPE, IC at the Vero cell
50In the nM scope, illustrate that HR2 polypeptide and derivative thereof can suppress the SARS virus cells infected, can be used for developing the medicine of preventing and treating SARS virus.
Sequence table
＜110〉Institute of Microorganism, Academia Sinica
＜120〉polypeptide drugs and its derivative and the application thereof of inhibition sars coronavirus
＜130〉Tian Bo
<170>PatentIn?Version 3.1
<210>1
<211>108
<212>PRT
<213>Coronavirus
<400>1
Leu Tyr Glu Asn Gln Lys Gln Ile Ala Asn Gln Phe Asn Lys Ala Ile
1 5 10 15
Ser Gln Ile Gln Glu Ser Leu Thr Thr Thr Ser Thr Ala Leu Gly Lys
20 25 30
Leu Gln Asp Val Val Asn Gln Asn Ala Gln Ala Leu Asn Thr Leu Val
35 40 45
Lys Gln Leu Ser Ser Asn Phe Gly Ala Ile Ser Ser Val Leu Asn Asp
50 55 60
Ile Leu Ser Arg Leu Asp Lys Val Glu Ala Glu Val Gln Ile Asp Arg
65 70 75 80
Leu Ile Thr Gly Arg Leu Gln Ser Leu Gln Thr Tyr Val Thr Gln Gln
85 90 95
Leu Ile Arg Ala Ala Glu Ile Arg Ala Ser Ala Asn
100 105
<210>2
<211>38
<212>PRT
<213>Coronavirus
<400>2
Gly Asp Ile Ser Gly Ile Asn Ala Ser Val Val Asn Ile Gln Lys Glu
1 5 10 15
Ile Asp Arg Leu Asn Glu Val Ala Lys Asn Leu Asn Glu Ser Leu Ile
20 25 30
Asp?Leu?Gln?Glu?Leu?Gly
35
Claims (8)
1. a polypeptide and an identical function derivative thereof of blocking the sars coronavirus cells infected is characterized in that it being from two heptad repeat regions of sars coronavirus spike (S) albumen (heptadrepeat, HR) polypeptide of HR1 and HR2 and derivative thereof.
The described HR1 of claim 1 it have the aminoacid sequence shown in the Seq ID:No.1.
3. the aminoacid sequence after prolongation on the sequence basis according to claim 2, brachymemma or some amino acid whose disappearance, insertion and the sudden change.
The described HR2 of claim 1 it have the aminoacid sequence shown in the Seq ID:No.2.
5. the aminoacid sequence after prolongation on the sequence basis according to claim 4, brachymemma or some amino acid whose disappearance, insertion and the sudden change.
6. polypeptide and the derivative thereof of described HR1 of claim 1 and HR2 have: polypeptide that HR1, HR2, HR1 are together in series and derivative thereof are called HR121 and derivative thereof; Polypeptide that HR2, HR1, HR2 are together in series and derivative thereof are called polypeptide and derivative thereof that HR212 and derivative thereof and HR1, HR2, HR1, five polypeptide of HR2, HR1 are together in series, are called 5-Helix and derivative thereof.
7. a method that obtains HR polypeptide or derivatives thereof comprises: according to the aminoacid sequence synthetic shown in Seq ID:No.1 or the Seq ID:No.2 or its derivative through chemically modified; Engineered method utilizes GST (glutathione S-transferase) amalgamation and expression to prepare polypeptide and derivative thereof.
8. claim 1 or 2 or 3 or 4 or 5 or 6 described polypeptide and derivative thereof the application in the anti-different sars coronavirus strain isolateds infection polypeptide drugs of preparation.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031362206A CN1223605C (en) | 2003-05-16 | 2003-05-16 | Polypeptide medicine for inhibiting SARS coronavirus, and derivatives and use thereof |
| PCT/CN2003/000457 WO2005080419A1 (en) | 2003-05-16 | 2003-06-12 | Polypeptide agent for inhibiting sars coronavirus and its derivatives and use thereof |
| AU2003246143A AU2003246143A1 (en) | 2003-05-16 | 2003-06-12 | Polypeptide agent for inhibiting sars coronavirus and its derivatives and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031362206A CN1223605C (en) | 2003-05-16 | 2003-05-16 | Polypeptide medicine for inhibiting SARS coronavirus, and derivatives and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1488641A true CN1488641A (en) | 2004-04-14 |
| CN1223605C CN1223605C (en) | 2005-10-19 |
Family
ID=34154758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031362206A Expired - Fee Related CN1223605C (en) | 2003-05-16 | 2003-05-16 | Polypeptide medicine for inhibiting SARS coronavirus, and derivatives and use thereof |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN1223605C (en) |
| AU (1) | AU2003246143A1 (en) |
| WO (1) | WO2005080419A1 (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100339396C (en) * | 2005-04-18 | 2007-09-26 | 中国科学院微生物研究所 | Multi-helix protein for inhibiting membrane virus infection, its coding gene and use |
| WO2009062348A1 (en) * | 2007-11-14 | 2009-05-22 | Institute Of Microbiology, Chinese Academy Of Sciences | Methods for inhibiting influenza virus infection and their drugs |
| CN101186637B (en) * | 2007-11-14 | 2011-09-14 | 中国科学院微生物研究所 | Method for inhibiting influenza virus infection and medicament thereof |
| CN1815234B (en) * | 2004-11-22 | 2012-05-02 | 香港大学 | Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof |
| CN107245095A (en) * | 2017-06-15 | 2017-10-13 | 武汉大学 | Peptide inhibitor for suppressing ten kinds of coronavirus |
| CN111349150A (en) * | 2020-03-24 | 2020-06-30 | 北京中科微盾生物科技有限责任公司 | Polypeptide for inhibiting novel coronavirus and application thereof |
| CN111518163A (en) * | 2020-04-08 | 2020-08-11 | 大连百奥泰科技有限公司 | Application of lipopeptide compounds in resisting novel coronavirus |
| CN112538105A (en) * | 2020-06-29 | 2021-03-23 | 斯克里普斯研究院 | Stable coronavirus spike (S) protein antigens and related vaccines |
| CN113264990A (en) * | 2020-02-14 | 2021-08-17 | 深圳大学 | Polypeptide for inhibiting novel coronavirus (SARS-COV-2) and application thereof |
| WO2021258250A1 (en) * | 2020-06-22 | 2021-12-30 | 中国科学院昆明动物研究所 | Use of interference polypeptide in preparation of anti-sars-cov-2 drug |
| WO2023039474A1 (en) * | 2021-09-08 | 2023-03-16 | Dana-Farber Cancer Institute, Inc. | Antiviral structurally-stapled sars-cov-2 peptide- cholesterol conjugates and uses thereof |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111647048B (en) * | 2020-06-22 | 2021-04-02 | 中国科学院昆明动物研究所 | Application of interference polypeptide in preparing anti-SARS-CoV-2 medicine |
| US11479582B2 (en) | 2020-10-16 | 2022-10-25 | King Faisal University | Anti-SARS-CoV-2 fusion peptides |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2282601B (en) * | 1993-09-16 | 1998-04-15 | Solvay | Antigenically-active proteins/polypeptides and coronavirus vaccines containing the same |
| AU7350798A (en) * | 1997-04-29 | 1998-11-24 | Universiteit Utrecht | Corona virus-like particles as tools for vaccination and therapy |
| US6623741B1 (en) * | 2000-02-29 | 2003-09-23 | Trimeris, Inc. | Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission |
| WO2001074295A2 (en) * | 2000-03-31 | 2001-10-11 | The Scripps Research Institute | Phospholipid scramblases and methods of use thereof |
-
2003
- 2003-05-16 CN CNB031362206A patent/CN1223605C/en not_active Expired - Fee Related
- 2003-06-12 AU AU2003246143A patent/AU2003246143A1/en not_active Abandoned
- 2003-06-12 WO PCT/CN2003/000457 patent/WO2005080419A1/en active Application Filing
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1815234B (en) * | 2004-11-22 | 2012-05-02 | 香港大学 | Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof |
| CN100339396C (en) * | 2005-04-18 | 2007-09-26 | 中国科学院微生物研究所 | Multi-helix protein for inhibiting membrane virus infection, its coding gene and use |
| WO2009062348A1 (en) * | 2007-11-14 | 2009-05-22 | Institute Of Microbiology, Chinese Academy Of Sciences | Methods for inhibiting influenza virus infection and their drugs |
| CN101186637B (en) * | 2007-11-14 | 2011-09-14 | 中国科学院微生物研究所 | Method for inhibiting influenza virus infection and medicament thereof |
| US8470771B2 (en) | 2007-11-14 | 2013-06-25 | Institute Of Microbiology, Chinese Academy Of Sciences | Method and medicament for inhibiting the infection of influenza virus |
| CN107245095B (en) * | 2017-06-15 | 2020-05-26 | 武汉大学 | Polypeptide inhibitor for inhibiting ten kinds of coronavirus |
| CN107245095A (en) * | 2017-06-15 | 2017-10-13 | 武汉大学 | Peptide inhibitor for suppressing ten kinds of coronavirus |
| CN113264990A (en) * | 2020-02-14 | 2021-08-17 | 深圳大学 | Polypeptide for inhibiting novel coronavirus (SARS-COV-2) and application thereof |
| CN111349150A (en) * | 2020-03-24 | 2020-06-30 | 北京中科微盾生物科技有限责任公司 | Polypeptide for inhibiting novel coronavirus and application thereof |
| CN111349150B (en) * | 2020-03-24 | 2021-02-09 | 北京中科微盾生物科技有限责任公司 | Polypeptide for inhibiting novel coronavirus and application thereof |
| CN111518163A (en) * | 2020-04-08 | 2020-08-11 | 大连百奥泰科技有限公司 | Application of lipopeptide compounds in resisting novel coronavirus |
| WO2021258250A1 (en) * | 2020-06-22 | 2021-12-30 | 中国科学院昆明动物研究所 | Use of interference polypeptide in preparation of anti-sars-cov-2 drug |
| CN112538105A (en) * | 2020-06-29 | 2021-03-23 | 斯克里普斯研究院 | Stable coronavirus spike (S) protein antigens and related vaccines |
| CN112538105B (en) * | 2020-06-29 | 2022-04-12 | 斯克里普斯研究院 | Stable coronavirus spike (S) protein antigens and related vaccines |
| WO2023039474A1 (en) * | 2021-09-08 | 2023-03-16 | Dana-Farber Cancer Institute, Inc. | Antiviral structurally-stapled sars-cov-2 peptide- cholesterol conjugates and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1223605C (en) | 2005-10-19 |
| AU2003246143A1 (en) | 2005-09-05 |
| WO2005080419A1 (en) | 2005-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1223605C (en) | Polypeptide medicine for inhibiting SARS coronavirus, and derivatives and use thereof | |
| CN101415723B (en) | HIV fusion inhibitor peptides with improved biological properties | |
| CN1038841C (en) | Polypeptide and anti-hiv agent prepared therefrom | |
| Krajewski et al. | Synthesis and HIV-1 integrase inhibitory activity of dimeric and tetrameric analogs of indolicidin | |
| CN111728963A (en) | Application of copper gluconate in preparing medicine for preventing or treating novel coronavirus infection | |
| CN104211799A (en) | Human-derived epidermal growth factor (EGF) structural domain protein and use thereof | |
| CN103755810A (en) | Long-acting HIV-1 membrane fusion inhibitor | |
| EP0371046A1 (en) | Synthetic peptides related to hiv-env proteins | |
| CN1980952A (en) | Multimerised HIV fusion inhibitors | |
| CN108484749B (en) | Recombinant soluble human bone-targeted interferon gamma-1 b and preparation method thereof | |
| CN102406929A (en) | Co-expressed molecular adjuvant enhanced divalent foot and mouth disease protein engineering vaccine | |
| CN106957803A (en) | One plant of clostridiopetidase A production bacterial strain and its collagenase gene sequence and application | |
| CN102311487A (en) | Anti-HIV (Human Immunodeficiency Virus) infection polypeptide, composition and application | |
| CN114539426A (en) | Fusion protein containing interferon alpha, recombinant strain expressing fusion protein and preparation method thereof | |
| CN112430588B (en) | Short peptide for resisting novel coronavirus infection and preparation method and application thereof | |
| CN113440603B (en) | Application of human alpha interferon subtype and receptor binding related site mutant in preparation of novel coronavirus infection prevention and treatment medicines | |
| EP1147132A2 (en) | Antiviral peptides | |
| US20010043931A1 (en) | Human respiratory syncytial virus | |
| CN1840544A (en) | ESC42 protein, preparation method and use thereof | |
| JP2007230903A (en) | Antiviral peptide and antiviral agent | |
| CN104311644B (en) | Polypeptide improves the purposes of method, pharmaceutical composition and the polypeptide of polypeptide stability in medicine preparation | |
| NZ303694A (en) | Use of viral material comprising msrv-1 or msrv-2 to prepare diagnostic, prophylactic and therapeutic compositions | |
| Engelbrecht et al. | Sequence note: Variation in HIV type 1 V3 region env sequences from Mozambique | |
| CN1165521A (en) | Phenyl peptides, method for preparing same, and pharmaceutical compositions containing said peptides | |
| EP0668872B1 (en) | Calcium channel blocking polypeptides from theraphosidae aphonopelma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20051019 Termination date: 20170516 |